Navigation Links
Orexigen(R) Therapeutics to Present at Upcoming Meetings
Date:5/13/2009

SAN DIEGO, May 13 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the following meetings:

    BIO 2009 Business Forum
    Date:  Tuesday, May 19, 2009
    Time:  9:20 a.m. - 9:35 a.m. Eastern
    Location:  Georgia World Congress Center, Room 316, Atlanta, Georgia
    Speaker:  Dr. Dennis Kim, Senior Vice President, Medical Affairs and
              Communications

    Eighth Annual JMP Securities Research Conference
    Date:  Tuesday, May 19, 2009
    Time:  9:00 a.m. - 9:30 a.m. Pacific
    Location:  The Ritz Carlton, San Francisco
    Speaker:  Graham Cooper, Chief Financial Officer

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at http://www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy
2. Orexigen(R) Therapeutics to Speak at Upcoming Conferences
3. Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results
4. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
5. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
6. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
7. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
8. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
9. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
10. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
11. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... June 21, 2017 , ... Beaker, ... executive talent in the life sciences industry, today announces a strategic partnership with ... partnership takes full advantage of Beaker’s expertise in executive recruitment solutions, providing Alcami ...
(Date:6/22/2017)... ... 22, 2017 , ... AESKU.GROUP, an innovation leader in ... Technologien GmbH, thereby expanding its product portfolio to include allergy and food intolerance ... atopic eczema or a food allergy. Allergies are escalating to epidemic proportions and ...
(Date:6/22/2017)... King of Prussia, PA (PRWEB) , ... June ... ... bringing industry knowledge and superior results to clients throughout the biopharma and life ... the rapid changes the industry is seeing. Tunnell’s Kip Wolf will be speaking ...
(Date:6/22/2017)... MA (PRWEB) , ... June 22, 2017 , ... Charm ... ILVO validation. The AMPH test was determined to be appropriate as a screening test ... visual interpretation, on the Charm EZ system, and the Charm EZ Lite system. These ...
Breaking Biology Technology:
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities ... (physiological and behavioral), by technology (fingerprint, AFIS, iris recognition, ... recognition, and others), by end use industry (government and ... immigration, financial and banking, and others), and by region ... , Asia Pacific , and ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Global ... to 2025" report to their offering. ... The Global Biometric Vehicle Access System Market ... the next decade to reach approximately $1,580 million by 2025. ... for all the given segments on global as well as regional ...
Breaking Biology News(10 mins):